Search alternatives:
associated decrease » associated increase (Expand Search), associated disease (Expand Search), associated diseases (Expand Search)
marked decrease » marked increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
associated decrease » associated increase (Expand Search), associated disease (Expand Search), associated diseases (Expand Search)
marked decrease » marked increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
-
2
-
3
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
4
-
5
-
6
-
7
Differential Gene Expression Associated with Non-Alcoholic Fatty Liver Disease.
Published 2025Subjects: -
8
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
9
Comparison of questionnaire scores among genotypes for the significant associations.
Published 2025Subjects: -
10
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20